AstraZeneca and Merck’s ovarian cancer drug Lynparza received U.S. regulatory approval for the treatment of advanced pancreatic cancer.
The U.S. Food and Drug Administration granted an expanded indication for GlaxoSmithKline’s oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor Zejula for wider use in treating ovarian cancer.
Researchers from the University of Maryland School of Medicine (UMSOM) published data from a proof-of-concept study in the journal PNAS that showed combining a PARP inhibitor with a DNMT inhibitor was effective in treating non-small cell lung cancer tumors.
AstraZeneca presented results for a late-stage clinical trial of Lynparza against prostate cancer, which the company hopes could lead to wider regulatory approval for more forms of the disease.
GlaxoSmithKline and AstraZeneca both reported late-stage clinical trial results that will likely make their competing medicines available to a wider group of ovarian cancer patients, possibly helping GSK catch the company’s rival in a highly contested drug class.
AstraZeneca made further headway in a race with competitor GlaxoSmithKline to use a promising new class of drugs to treat ovarian cancer.
The European Commission approved Pfizer Inc.’s Talzenna (talazoparib), an oral polypolymerase inhibitor, as monotherapy for the treatment of adult patients with germline breast cancer susceptibility gene 1/2-mutations who have human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer.
Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission.
In GlaxoSmithKline’s first-quarter 2019 report was an announcement that the global pharma giant cut the development of two vaccine programs – one for strep pneumonia and the other for a universal flu vaccine.
AstraZeneca Plc said the British drugmaker’s cancer drug being jointly developed with U.S.-based Merck & Co. met the primary goal in a late-stage study for a rare type of pancreatic cancer.